RECRUITING

Novel Digital Application for Patients With Acute Leukemia

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This research study is evaluating to examine the efficacy of a novel a self-administered digital application (DREAMLAND) for improving patients' long-term quality of life and psychological outcomes for patients with acute myeloid leukemia undergoing intensive chemotherapy.

Official Title

Multi-Site Randomized Controlled Trial of a Novel Digital Application (DREAMLAND) to Improve Outcomes for Patients With Acute Myeloid Leukemia

Quick Facts

Study Start:2024-10-21
Study Completion:2030-04-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06472128

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 120 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Hospitalized patients (age \> 18 years) with a diagnosis of AML.
  2. * Initiating treatment with either intensive chemotherapy (7+3) or modification of this regimen on a clinical trial, or a similar intensive regimen that typically requires a prolonged 3-6-week hospitalization and/or recovery.
  3. * Ability to comprehend and speak English as the digital apps are only available in English
  1. * Patients with a diagnosis of acute promyelocytic leukemia
  2. * Patients with acute or unstable psychiatric or cognitive conditions which the treating clinicians believes prohibits informed consent or compliance with study procedures.

Contacts and Locations

Study Contact

Areej El-Jawahri, MD
CONTACT
617-724-4000
ael-jawahri@mgb.org
Upeka Samarakoon, PhD
CONTACT
ssamarakoon@mgh.harvard.edu

Study Locations (Sites)

Massachusetts General Hospital (MGH)
Boston, Massachusetts, 02114
United States
Duke University
Durham, North Carolina, 27710
United States
Fred Hutchinson Cancer Research Center (FHCRC)
Seattle, Washington, 98109
United States

Collaborators and Investigators

Sponsor: Massachusetts General Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-10-21
Study Completion Date2030-04-30

Study Record Updates

Study Start Date2024-10-21
Study Completion Date2030-04-30

Terms related to this study

Additional Relevant MeSH Terms

  • Relapsed Adult Acute Myeloid Leukemia
  • Primary Refractory Acute Myeloid Leukemia
  • High Risk Acute Myeloid Leukemia